Macromolecular Prodrug for Ulcerative Colitis

An oral, liquid pharmaceutical that provides localized release

  • Orally administered macromolecular drug
  • Prodrug formulation
  • Localized release
  • Minimal local, systemic toxicity

Licensing Manager:Catherine Murari-Kanti, Ph.D. or at 402-559-3265


An oral, liquid pharmaceutical that provides localized release

colonoscopy study results

Colonoscopy analysis on day 28. (A) Colonoscopy images recorded in the distal colon. Blue arrow indicates loss of vascular pattern; red arrow indicates bleeding; and white arrow indicates irregularities. (B) Colonoscopy score results evaluated by a gastroenterologist (DDE) according to the endoscopic colitis grading criteria in Table 2.2. *, P ≤ 0.05.

UNMC researchers have developed a macromolecular prodrug of dexamethasone to improve the treatment of inflammatory bowel disease.
This liquid pharmaceutical formulation can be orally administrated to Ulcerative Colitis patients. It will continue to be stable through the gastrointestinal tract and eventually get internalized by the immunocytes at the Ulcerative Colitis disease sites to release the drug payload. This release happens as a result of the chemical structure of the prodrug, thus reducing local and systemic toxicity. Also, the unique chemical design clears the drug from the system along with food.
In vivo studies with mice induced to have ulcerative colitis, the macromolecular drug improved stool consistency and apparently decreased mortality.
The mouse study also showed:

  • Colon weight-to-length ratio was significantly reduced
  • No adrenal gland atrophy
  • Histological evaluation further confirmed therapeutic efficacy
  • Colonoscopy evaluation showed similar distinct vasculature to healthy group without abnormal signs

To learn more about the macromolecular prodrug for ulcerative colitis or to discuss licensing and collaboration opportunities, please contact Catherine Murari-Kanti, Ph.D. or at 402-559-3265.